Edition:
India

EyeGate Pharmaceuticals Inc (EYEG.OQ)

EYEG.OQ on NASDAQ Stock Exchange Capital Market

1.20USD
2:29am IST
Change (% chg)

$-0.04 (-3.23%)
Prev Close
$1.24
Open
$1.21
Day's High
$1.23
Day's Low
$1.15
Volume
45,263
Avg. Vol
35,013
52-wk High
$3.89
52-wk Low
$0.90

Latest Key Developments (Source: Significant Developments)

Eyegate Promotes Sarah Romano To CFO
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Eyegate Pharmaceuticals Inc ::EYEGATE PROMOTES SARAH ROMANO TO CHIEF FINANCIAL OFFICER.EYEGATE PHARMACEUTICALS-ANNOUNCED PROMOTION OF SARAH ROMANO FROM INTERIM CFO TO CFO, EFFECTIVE JANUARY 1, 2018.  Full Article

EyeGate Achieves 75 Pct Enrollment In Pivotal Phase 3 Clinical Trial For Anterior Uveitis Triggering Milestone Payment
Monday, 18 Dec 2017 

Dec 18 (Reuters) - EyeGate Pharmaceuticals Inc ::EYEGATE ACHIEVES 75% ENROLLMENT IN PIVOTAL PHASE 3 CLINICAL TRIAL FOR ANTERIOR UVEITIS TRIGGERING MILESTONE PAYMENT.EYEGATE PHARMACEUTICALS INC - TOPLINE DATA IS EXPECTED TO BE RELEASED IN Q2 OF 2018..EYEGATE PHARMA - REMAIN ON-TRACK TO REPORT TOPLINE DATA FROM TRIAL IN Q2 2018, WITH EXPECTED NDA FILING FOR EGP-437 IN ANTERIOR UVEITIS NEXT YEAR.  Full Article

Eyegate Pharmaceuticals posts Q3 ‍net loss $4.1 mln vs $3.4 mln a year ago
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Eyegate Pharmaceuticals Inc :Eyegate Pharmaceuticals reports third quarter 2017 financial results and provides business update.Eyegate Pharmaceuticals Inc - ‍net loss in Q3 of 2017 was $4.1 million, compared with $3.4 million in Q3 of 2016​.  Full Article

EyeGate completes enrollment in phase 2b clinical trial of EGP-437 for cataract surgery
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - EyeGate Pharmaceuticals Inc :EyeGate completes enrollment in phase 2b clinical trial of EGP-437 for cataract surgery.Eyegate Pharmaceuticals Inc - ‍topline data is expected to be released in Q1 of 2018 for phase 2b clinical trial of EGP-437 for cataract surgery​.  Full Article

Eyegate says selling stockholders may offer up to 871,000 shares of co's common stock
Thursday, 1 Sep 2016 

Eyegate Pharmaceuticals Inc : Says selling stockholders may offer up to 871,000 shares of co's common stock - SEC filing Source: (http://bit.ly/2c1ebmt) Further company coverage: [EYEG.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Eyegate Pharma Q2 net loss $3.823 million
Thursday, 11 Aug 2016 

Eyegate Pharmaceuticals Inc : Eyegate pharmaceuticals reports second quarter 2016 financial results and provides business update .Says net loss for q2 of 2016 was $3.823 million, compared with loss of $1.541 million in q2 of 2015.  Full Article

Eyegate Pharmaceuticals files for mixed shelf of up to $100 mln - SEC filing
Monday, 27 Jun 2016 

Eyegate Pharmaceuticals Inc : Files for mixed shelf of up to $100 million - SEC filing Source: (http://1.usa.gov/291KTCy ) Further company coverage: [EYEG.O] (Bengaluru Newsroom: +1 646 223 8780).  Full Article

Eyegate announces data from phase 1B/2A trial of EGP-437
Wednesday, 1 Jun 2016 

EyeGate Pharmaceuticals Inc : Majority of subjects treated to-date in two higher dose cohorts displayed clinically relevant reductions in anterior chamber cell count (ACC) . Expect to complete trial in Q3 of 2016 .Eyegate Announces Encouraging Interim Data From Phase 1b/2a Clinical Trial Of EGP-437 for treatment of ocular inflammation and pain post cataract surgery.  Full Article

Eyegate Pharma Q1 net loss $2.4 million
Saturday, 14 May 2016 

Eyegate Pharmaceuticals Inc : Continue to expect initiation of first clinical trial for jde-003 in treatment of corneal repair by end of year . Targeting top-line data from phase 1b / 2a trials of egp-437 in macular edema and cataract surgery by end of q2 . Net loss for q1 of 2016 was $2.442 million versus net loss of $11.028 million .Eyegate pharmaceuticals reports first quarter 2016 financial results and provides business update.  Full Article

EyeGate Pharmaceuticals, Inc announces CFO change
Thursday, 28 Apr 2016 

EyeGate Pharmaceuticals, Inc:Effective April 25, 2016. Mr. Brenneman will lead the Company's financial and administrative operations.  Full Article

BRIEF-Eyegate Promotes Sarah Romano To CFO

* EYEGATE PHARMACEUTICALS-ANNOUNCED PROMOTION OF SARAH ROMANO FROM INTERIM CFO TO CFO, EFFECTIVE JANUARY 1, 2018 Source text for Eikon: Further company coverage: